Nimbus Therapeutics
25 First Street
Suite 404
Cambridge
Massachusetts
02141
United States
Tel: 857-999-2009
Fax: 617-231-0652
Website: http://www.nimbusdiscovery.com/
98 articles about Nimbus Therapeutics
-
Nimbus Therapeutics Appoints Peter Tummino, Ph.D., as Chief Scientific Officer
2/14/2019
Nimbus Therapeutics today announced the appointment of Peter Tummino Ph.D. to Chief Scientific Officer.
-
Nimbus Therapeutics Strengthens Leadership Team
1/3/2019
Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced the promotion of Holly Whittemore, C.P.A., to Chief Financial Officer and Abbas Kazimi to Vice President of Business Development
-
Biotech Movers and Shakers for Oct. 8
10/8/2018
Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions. -
Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer
10/4/2018
Nimbus Therapeutics, a biotechnology company applying deep computational chemistry expertise throughout drug discovery and development, has named Jeb Keiper, M.S., M.B.A., President and Chief Executive Officer, effective immediately.
-
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
-
Navitor Appoints New CEO
8/3/2018
Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer. -
HotSpot Therapeutics Emerges From Stealth Mode With $45 Million to Aim at New Biological Targets
7/17/2018
HotSpot Therapeutics burst forth from stealth mode with $45 million in Series A funding to support the development of therapies that will target natural “regulatory hotspots.” -
Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology
7/9/2018
Nimbus Therapeutics announced that Adrian Ray, Ph.D., has joined the company as the Senior Vice President of Discovery Biology.
-
Metracrine, based in San Diego, completed a Series C financing round worth $65 million.
-
Nimbus Therapeutics, raised an additional $65 million in financing.
-
Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
6/5/2018
New capital to accelerate the company’s pipeline progress and fuel its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, oncology and metabolic disease
-
Nimbus Therapeutics Announces Departure of Chief Scientific Officer Rosana Kapeller, M.D., Ph.D.
3/8/2018
Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, announced today that Rosana Kapeller has resigned from the company after more than eight years of success to explore an executive leadership role.
-
Nimbus Therapeutics Enters Into Strategic Partnership With Charles River To Advance New Therapeutic Programs
4/5/2017
-
Nimbus Therapeutics Appoints Mark Ashwell, Ph.D., As Head Of Chemistry
1/5/2017
-
Nimbus Therapeutics Announces $200 Million Milestone Payment From Gilead For Allosteric ACC Inhibitor Program In Non-alcoholic Steatohepatitis (NASH)
11/2/2016
-
Nimbus Therapeutics Announces Closing Of Gilead’ Acquisition Of Nimbus Apollo, Inc., And Its Acetyl-CoA Carboxylase (ACC) Inhibitor Program
5/17/2016
-
Nimbus Therapeutics Granted Fast Track Designation For Its Allosteric ACC Inhibitor, NDI-010976, For The Treatment Of NASH
2/2/2016
-
Nimbus Therapeutics Achieves Second Milestone In Research Collaboration With Monsanto
12/23/2015
-
Nimbus Therapeutics Announces Progress On Key Therapeutic Programs
11/10/2015
-
Nimbus Therapeutics Scores a Global License Agreement with Genentech, Financial Terms Undisclosed
10/20/2015